

**Assessment of the Efficacy of Autologous PRP Injection and To Compare It with Corticosteroid Injection in Treatment of Plantar Fasciitis (PF)**Durga Shankar Meena<sup>1</sup>, Kirti R. Ramnani<sup>2</sup>, Ashiwani Kumar Pankaj<sup>3</sup><sup>1</sup>Assistant Professor, Department of Orthopaedics, Lord Buddha Koshi Medical College and Hospital, Saharsa, Bihar, India<sup>2</sup>Associate Professor, Department of Orthopaedics, Lord Buddha Koshi Medical College and Hospital, Saharsa, Bihar, India<sup>3</sup>Assistant Professor, Department of Orthopaedics, Shri Ramkrishna Institute of Medical Sciences & Sanaka Hospital, Durgapur, West Bengal, India

Received: 15-06-2023 / Revised: 19-07-2023 / Accepted: 10-08-2023

Corresponding Author: Dr. Kirti R. Ramnani

Conflict of interest: Nil

**Abstract****Aim:** The aim of the present study was to assess the efficacy of autologous PRP injection and to compare it with corticosteroid injection in treatment of plantar fasciitis (PF).**Methods:** The study was conducted in the Department of Orthopaedics for the period of 2 years. 120 patients were included in the study and divided into two groups. Group I (60 patients) received PRP injection and group II (60 patients) were given steroid injection.**Results:** A total of 120 patients were analyzed in this study ranging from 21 to 65 years of age. In both groups, females outnumbered males, right sided involvement was more than the left side. The average duration of symptoms at the time of presentation was observed to be  $22.18 \pm 12.48$  and  $19.5 \pm 15.45$  in group A and group B respectively. The clinical improvement in chronic plantar fasciitis in this study was evaluated by comparing the values of functional outcome indices at 6th month follow-up with the baseline values recorded prior to administration of injection. The patients showed a statistically significant improvement in both groups with respect to AOFAS Score, VAS scores and plantar fascia thickness and this improvement was significantly more in Group A (PRP). Both the groups do not differ significantly at baseline and posttreatment at 6 months ( $p > 0.05$ ).**Conclusion:** This study concluded that both PRP and corticosteroid (methyl prednisolone) injections provide symptomatic relief in the treatment of chronic plantar fasciitis. Though the corticosteroid (methyl prednisolone) injection was effective for immediate pain relief, PRP injections are more effective than corticosteroid (methyl prednisolone) injections on long term basis.**Keywords:** AOFAS, Corticosteroid, Plantar fasciitis, Platelet rich plasmaThis is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.**Introduction**

Plantar fasciitis (PF), better termed as plantar fasciosis [1,2], is a degeneration of plantar fascia leading to an inflammatory reaction. [3] It occurs mostly due to the biomechanical stress on the plantar fascia. [4] The plantar fascia is a thin elastic fibrous band of connective tissue aligned in a longitudinal orientation with a rich extracellular matrix predominantly in the Hyaluronan. [5] Fasciocytes, a new cell found in the plantar fascia, first termed by Stecco et al., 2018 is devoted to the production of hyaluronan, which promotes the gliding function between the deep fascia and muscle. [6] Plantar fascia lies in close connectivity to the para tendon of Achilles through the heel periosteum. Therefore, any degenerative or inflammatory process within the para tendon of Achilles can hinder normal foot

kinematics rendering plantar fascia thickness increment leading to plantar fasciitis. [7] The PF worsens the quality of life [8,9] with a lifetime global prevalence of 10% [10], more common in females than males [11] due to the difference in lifestyle and health status between both sexes. [12]

Corticosteroid (CS) injections have served as the traditional method of injection therapy for many years. CS injections are effective because of their inherent anti-inflammatory properties; however, they are also associated with a risk of plantar fascia rupture and fat pad atrophy. [13] Furthermore, while CS may provide short-term pain relief, its long-term benefit in plantar fasciitis is questionable. A recent

Cochrane review did not find any long-term benefit of CS over a placebo at 6-month follow-up. [14]

With concerns regarding the long-term benefits of CS mounting, attention has been directed at other injection therapies that may offer longer term benefits. Platelet rich plasma (PRP) has become increasingly utilized as a biologic option in the treatment of plantar fasciitis. [15] Similar to CS, PRP has strong anti-inflammatory properties, but without known adverse effects on the plantar fascia structure. PRP contains high levels of growth factors and anti-inflammatory cytokines, which basic science studies have shown to potentially ameliorate degenerative conditions.<sup>16</sup> While PRP has been shown to be beneficial for other degenerative conditions, there is no consensus on its use for plantar fasciitis.

The aim of the present study was to assess the efficacy of autologous PRP injection and to compare it with corticosteroid injection in treatment of plantar fasciitis (PF).

### Materials and Methods

The study was conducted in the Department of Orthopaedics, Lord Buddha Koshi Medical College and Hospital, Saharsa, Bihar, India for the period of 2 years. 120 patients were included in the study and divided into two groups. Group I (60 patients) received PRP injection and group II (60 patients) were given steroid injection. The diagnosis of PF is made with a reasonable level of certainty on the basis of history, clinical, and radiological assessment.

### Inclusion Criteria

- Patients between age group of 18 to 60 years presenting with complaints of plantar heel pain, worse with rising in morning and/or after periods of sitting or lying presenting for 4 weeks or more
- Patients with maximal tenderness at the attachment of the plantar fascia on the medial tubercle of the calcaneus
- Willingness to participate in an investigational technique and follow-up with written consent
- Willingness to forgo any other concomitant conservative treatment modality; NSAIDs and orthotic devices during the study period.

### Exclusion Criteria

- Previous surgery for heel pain
- Patient with neuropathic symptoms (radiculopathy, tarsal tunnel syndrome, tarsi sinus syndrome)
- Patient with complex regional pain syndrome or with metastatic cancer
- Achilles tendon pathology

- Systemic diseases like inflammatory or degenerative polyarthritis, diabetes mellitus, local or systemic infection, peripheral vascular diseases, metabolic disease, such as gout, clotting disorder, anticoagulation therapy
- Pregnant or breastfeeding female patients
- Dysfunction of the knee, ankle, or foot
- Work-related or compensable injury
- Previous treatment: Corticosteroid injection in the last 6 months or NSAIDs treatment within the last 7 day.

### Method

After taking clearance from ethical committee, patients were selected according to inclusion and exclusion criteria. Informed written consent was taken from every patient who agreed to follow instructions and recommendations given by the clinician. Patient biography, detailed history, and clinical examination were done along with ultrasonographic evaluation of plantar fascia thickness of both feet. All the fresh cases were initially treated with contrast bath, foot-stretching exercise, and silicon heel pad for 4 weeks. The patients, who were not improved with initial treatment, were explained about the autologous PRP injection and steroid injection.

Patients were randomly allocated into two groups

- Group I: These patients were treated with single injection of 3 mL autologous PRP injection locally.
- Group II: These patients were treated with single injection of 3 cc, i.e., 80 mg methylprednisolone acetate locally.

### Platelet-rich Plasma Preparation Method

A total of 20 mL of a patient's own venous blood was withdrawn from antecubital vein under aseptic conditions and was collected in presterilized centrifuge vials. These centrifuge vials were preloaded with anticoagulant acid citrate dextrose. This blood was then centrifuged at 3200 rpm for 15 minutes. The blood is then separated into platelet-poor plasma (PPP) and PRP. The PPP is extracted and discarded. The resulting platelets concentrate contains approximately 6 to 8 times the concentration of platelets compared to baseline whole blood. The PRP samples were sent to pathology lab at different intervals to know the concentration of platelets. The average platelet concentration in our sample was found to be 6.4 (SD  $\pm$  1.2) times the baseline level.

### Injection Technique

The procedure was done on an outpatient basis and under complete aseptic conditions. Sites of maximum tenderness were pre-marked with a sterile marker. Patients of group I received a 3 cc PRP injection into the origin of the plantar fascia at

the site of maximum tenderness. 2 cc of 2% Lidocaine was infiltrated prior to injection. A peppering technique, i.e., spreading in clockwise manner was used to achieve a more extensive zone of delivery, with a single skin portal and four to five passes through the fascia itself. Lidocaine sensitivity was done before starting the procedure. Patients are rested for 15 minutes and then they are allowed to walk.

Group II patients received 2 mL of depomedrol (80 mg methylprednisolone) locally. About 2 mL of 2% lidocaine was infiltrated prior to this as in group I. The patients were monitored for 20 minutes for adverse reactions and then sent home with instructions to limit their use of the feet for approximately 48 hours and use opioid for pain. After 48 hours, patients were given a standardized stretching protocol to follow for 2 weeks. A formal strengthening program is initiated after this stretching. At 4 weeks after the procedure, patients were allowed to proceed with normal sporting or recreational activities as tolerated. Any types of foot orthoses were not advised.

### Follow-up

The patients were evaluated with visual analogue scale (VAS) and AOFAS at the time of getting the injection (0 weeks), at the end of 6th week, 12th week and 6 months of follow up and plantar fascia thickness using USG at 0 week and 6 months of follow-up.

### Statistical Analysis

Descriptive statistics were used for baseline parameters of the data. Qualitative variables were presented as mean and standard deviations and qualitative variables in counts and percentages. For the pre post comparison of quantitative outcome measures either a paired t test was used as per the normality of the data. A "p" value lesser than 0.05 showed statistical significance. All data entered in Microsoft excel and analyzed using SPSS version 22.

### Results

**Table 1: Demographic details**

Parameters	Group A(PRP)	Group B(steroid)
Sex (M/F)	28/32	26/34
Age	45±12.88	37.3±13.07
Side(bilateral/left/right)	7/23/30	6/26/28
Duration of symptoms(weeks)	22.18±12.48	19.5±15.45

A total of 120 patients were analyzed in this study ranging from 21 to 65 years of age. In both groups, females outnumbered males, right sided involvement was more than the left side. The average duration of symptoms at the time of presentation was observed to be 22.18±12.48 and 19.5±15.45 in group A and group B respectively.

**Table 2: Functional and radiological outcome analysis between the two groups**

Parameters	Follow-up	Group-A (PRP)	Group-B (steroids)	P-value
AOFAS	Baseline	53.07±3.16	54.76±3.05	0.38
	6 weeks	82.78±1.76	85±2.25	0.0001
	12 weeks	85.35±2.25	78.62±2.48	0.0001
	6 months	87.63±1.47	77.13±2.04	0.0001
VAS	Baseline	8.06±0.56	8.42±0.68	0.132
	6 weeks	7.06±0.74	4.88±1.04	0.0001
	12 weeks	6.24±0.86	4.06±0.74	0.0007
	6 months	2.8±1.06	4.42±0.94	0.0001
Plantar fascia thickness	Baseline	5.85±0.65	5.65±0.75	0.40
	6 months	3.33±0.47	3.74±0.66	0.007

The clinical improvement in chronic plantar fasciitis in this study was evaluated by comparing the values of functional outcome indices at 6th month follow-up with the baseline values recorded prior to administration of injection. The patients showed a

statistically significant improvement in both groups with respect to AOFAS Score, VAS scores and plantar fascia thickness and this improvement was significantly more in Group A (PRP).

**Table 3: Test of significance of plantar fascia thickness in groups I and II**

Groups	Mean plantar fascia thickness pretreatment	Mean plantar fascia thickness posttreatment	p-value
A	6.200	3.917	<0.001
B	5.834	4.156	<0.001

Both the groups do not differ significantly at baseline and posttreatment at 6 months ( $p > 0.05$ ).

### Discussion

Plantar fasciitis (PF) accounts for 15% of all foot disorders. More than 10% of the population is affected by it over their lifetime. [17-19] Although etiology of PF remains ill-understood, but there are evidences to suggest that it is probably initiated by repeated microtrauma. Pathological changes are degenerative in nature (although partially reversible) and histologically changes, such as, collagen necrosis, angiofibroblastic hyperplasia, chondroid metaplasia and matrix calcification are seen. [20-22] The most common presenting symptom of PF is a sharp pain of insidious onset with maximal tenderness at the anterior medial border of the calcaneus. [23] The pain is typically worst on the first few steps in the morning and with initial steps after prolonged sitting or inactivity, and on examination, there is mild to severe tenderness on medial calcaneal tubercle and sometimes, on lateral aspect of heel. [24]

A total of 100 patients were analyzed in this study ranging from 22 to 64 years of age. In both groups, females outnumbered males, right sided involvement was more than the left side. The average duration of symptoms at the time of presentation was observed to be  $23.17 \pm 12.48$  and  $18.4 \pm 14.48$  in group A and group B respectively. This result was similar to the study conducted by Shetty et al [25] wherein the mean patient age in the PRP Group and steroid group was  $34.0 \pm 9.15$  and  $39.2 \pm 9.35$  respectively. The gender distribution observed in our study was similar to Monto et al [26] that included 8 males and 12 females in the PRP Group, and 9 males and 11 females in the steroid Group. Plantar fasciitis is commonly diagnosed inferior heel pain in adults and have a dramatic impact on physical mobility. [27] It continues to baffle doctors, since there are no definite combinations of clinical, biomechanical, or training variables, or causative factors in the development of chronic plantar fasciitis have been found. [28] Though corticosteroid injections are considered as one of the treatment modalities but unfortunately it has short term results and is associated with complications like rupture of plantar fascia and fat atrophy. [29]

The clinical improvement in chronic plantar fasciitis in this study was evaluated by comparing the values of functional outcome indices at 6th month follow-up with the baseline values recorded prior to administration of injection. The patients showed a statistically significant improvement in both groups with respect to AOFAS Score, VAS scores and plantar fascia thickness and this improvement was significantly more in Group A (PRP). Mahindra et al assessed the visual analog scale for pain and with

the American orthopaedic foot and ankle society (AOFAS) ankle and hindfoot score before injection, at 3 weeks, and at 3-month follow-up. [30] Mean visual analog scale score in the platelet-rich plasma and corticosteroid groups decreased from 7.44 and 7.72 pre-injection to 2.52 and 3.64 at final follow-up, respectively. Mean AOFAS score in the platelet-rich plasma and corticosteroid groups improved from 51.56 and 55.72 pre-injection to 88.24 and 81.32 at final follow-up, respectively. In another study by Tank et al, within group comparison in PRP group the results were statistically significant ( $p < 0.05$ ). [31] Both the groups do not differ significantly at baseline and posttreatment at 6 months ( $p > 0.05$ ). A study performed by Aksahin et al [32] compared the effects of corticosteroid injections and PRP injections to treat PF. Their study consisted of 60 patients who did not respond to conservative treatment for at least 3 months prior to either injection. The patients were placed into two groups in which 30 patients were treated with a corticosteroid injection and 30 patients were treated with a PRP injection. They found no significant difference in pain or patient satisfaction, thus demonstrating that PRP injections are as effective as corticosteroid injections.

### Conclusion

This study concluded that both PRP and corticosteroid (methyl prednisolone) injections provide symptomatic relief in the treatment of chronic plantar fasciitis. Though the corticosteroid (methyl prednisolone) injection was effective for immediate pain relief, PRP injections are more effective than corticosteroid (methyl prednisolone) injections on long term basis.

### References

1. Schwartz EN, Su J. Plantar fasciitis: a concise review. *The Permanente Journal*. 2014;18(1):e105.
2. Alanazi M, Khan R, Muqri A, Alnoaier Z, Dalak M, Alajlani S, Hamdi AD, Alghamdi TA, Alrawaili SD. Plantar fasciitis in primary care: a review. *Int J Med Dev Ctries*. 2022 Jul 8;6(7):1002-5.
3. Luffy L, Grosel J, Thomas R, So E. Plantar fasciitis: a review of treatments. *JAAPA*. 2018 Jan 1;31(1):20-4.
4. Chen CM, Lee M, Lin CH, Chang CH, Lin CH. Comparative efficacy of corticosteroid injection and non-invasive treatments for plantar fasciitis: a systematic review and meta-analysis. *Scientific reports*. 2018 Mar 5;8(1):4033.
5. Todros S, Biz C, Ruggieri P, Pavan PG. Experimental analysis of plantar fascia mechanical properties in subjects with foot pathologies. *Applied Sciences*. 2021 Feb 8;11(4):1517.
6. Stecco C, Fede C, Macchi V, Porzionato A, Petrelli L, Biz C, Stern R, De Caro R. The

- fasciocytes: A new cell devoted to fascial gliding regulation. *Clinical Anatomy*. 2018 Jul;31(5): 667-76.
7. Stecco C, Corradin M, Macchi V, Morra A, Porzionato A, Biz C, De Caro R. Plantar fascia anatomy and its relationship with Achilles tendon and paratenon. *Journal of anatomy*. 2013 Dec;223(6):665-76.
  8. Poenaru D, Badoiu SC, Ionescu AM. Therapeutic considerations for patients with chronic plantar fasciitis. *Medicine International*. 2021 Sep 1;1(4):1-5.
  9. Cotchett M, Rathleff MS, Dilnot M, Landorf KB, Morrissey D, Barton C. Lived experience and attitudes of people with plantar heel pain: a qualitative exploration. *Journal of foot and ankle research*. 2020 Dec;13:1-9.
  10. Trojjan T, Tucker AK. Plantar fasciitis. *American family physician*. 2019 Jun 15;99(12): 744-50.
  11. Orchard J. Plantar fasciitis. *Bmj*. 2012 Oct 10; 345.
  12. Palomo-López P, Becerro-de-Bengoa-Vallejo R, Losa-Iglesias ME, Rodríguez-Sanz D, Calvo-Lobo C, López-López D. Impact of plantar fasciitis on the quality of life of male and female patients according to the Foot Health Status Questionnaire. *Journal of pain research*. 2018 Apr 27:875-80.
  13. Acevedo JI, Beskin JL. Complications of plantar fascia rupture associated with corticosteroid injection. *Foot & ankle international*. 1998 Feb;19(2):91-7.
  14. David JA, Sankarapandian V, Christopher PR, Chatterjee A, Macaden AS. Injected corticosteroids for treating plantar heel pain in adults. *Cochrane Database of Systematic Reviews*. 2017(6).
  15. Zhang JY, Fabricant PD, Ishmael CR, Wang JC, Petrigliano FA, Jones KJ. Utilization of platelet-rich plasma for musculoskeletal injuries: an analysis of current treatment trends in the United States. *Orthopaedic journal of sports medicine*. 2016 Dec 21;4(12):23259-67116676241.
  16. Baksh N, Hannon CP, Murawski CD, Smyth NA, Kennedy JG. Platelet-rich plasma in tendon models: a systematic review of basic science literature. *Arthroscopy: The Journal of Arthroscopic & Related Surgery*. 2013 Mar 1; 29(3):596-607.
  17. Sorrentino F, Iovane A, Vetro A, Vaccari A, Midiri M. Role of high-resolution ultrasound in guiding treatment of idiopathic plantar fasciitis with minimally invasive techniques. *Radiol Med* 2008 Jan;113(4):486-495.
  18. Buchbinder R. Clinical practice. Plantar Fasciitis. *New Engl J Med* 2004 May;350(21): 2159-2166.
  19. Singh D, Angel J, Bentley G, Trevino S. Fortnightly review: Plantar fasciitis. *BMJ* 1997 Jul 19;315(7101):172-175.
  20. Lemont H, Ammirati KM, Usen N. Plantar fasciitis: a degenerative process (fasciosis) without inflammation. *J Am Podiatr Med Assoc* 2003 May-Jun;93(3):234-237.
  21. Snider MP, Clancy WG, McBeath AA. Plantar fascia release for chronic plantar fasciitis in runners. *Am J Sports Med* 1983 Jul-Aug;11: 215-219.
  22. Tountas AA, Fornasier VL. Operative treatment of subcalcaneal pain. *Clin Orthop Relat Res* 1996 Nov;(332):170-178.
  23. Jarde O, Diebold P, Havet E, Boulu G, Vernois J. Degenerative lesions of the plantar fascia: surgical treatment by fasciectomy and excision of the heel spur. A report on 38 cases. *Acta Orthop Belg* 2003 Jun;69(3):276-274.
  24. American College of Foot and Ankle Surgeons. The diagnosis and treatment of heel pain. *J Foot Ankle Surg* 2001 Sep-Oct;40(5): 329-340.
  25. Shetty VD, Dhillon M, Hegde C, Jagtap P, Shetty S. A study to compare the efficacy of corticosteroid therapy with platelet-rich plasma therapy in recalcitrant plantar fasciitis: a preliminary report. *Foot Ankle Surg*. 2014; 20(1) :10-3.
  26. Monto RR. Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis. *Foot Ankle Int*. 2014;35(4):313-8.
  27. Singh D, Angel J, Bentley G, Trevino SG. Fortnightly review. Plantar fasciitis. *BMJ*. 1997;315(7101):172-5.
  28. Beeson P. Plantar fasciopathy: revisiting the risk factors. *Foot Ankle Surg*. 2014;20(3):160-5.
  29. Acevedo JI, Beskin JL. Complications of plantar fascia rupture associated with corticosteroid injection. *Foot Ankle Int*. 1998;19(2):91-7.
  30. Mahindra P, Yamin M, Selhi HS, Singla S, Soni A. Chronic plantar fasciitis: effect of platelet-rich plasma, corticosteroid, and placebo. *Orthopedics*. 2016;39(2):e285-9.
  31. Tank G, Gupta R, Gupta G, Rohila R. Comparative study of platelet-rich plasma and corticosteroid injection in the treatment of plantar fasciitis. *J Foot Ankle Surg*. 2017;4(2):84-9.
  32. Akşahin E, Doğruyol D, Yüksel HY, Hapa O, Doğan Ö, Çelebi L, Biçimoğlu A. The comparison of the effect of corticosteroids and platelet-rich plasma (PRP) for the treatment of plantar fasciitis. *Archives of orthopaedic and trauma surgery*. 2012 Jun;132:781-5.